Overview

A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

Status:
Active, not recruiting

Trial end date:
2021-11-29

Target enrollment:

Participant gender:

Summary

The study seeks to evaluate the efficacy and tolerability of veliparib/placebo in combination with carboplatin and paclitaxel in HER2-negative metastatic or locally advanced, unresectable, BRCA-associated breast cancer.

Phase:

Phase 3

Details

Lead Sponsor:

AbbVie

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel
Poly(ADP-ribose) Polymerase Inhibitors
Veliparib